Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committee 2023
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
      • R&D Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact

Synact in Media

2020
  • 2023
  • 2022
  • 2021
  • 2019
  • 2018
  • All years
November 11, 2020

SynAct Pharma mentioned in the Rheumatoid Arthritis (RA) – Pipeline Insight, 2020

September 23, 2020

DI (Nyhetsbyrån Direkt): Synact Pharma startar fas 2-studie med covid-patienter

September 22, 2020

BIOSTOCK: SynAct Pharma sees potential in several viral diseases

September 22, 2020

BIOSTOCK: SynAct Pharma ser potential inom flera virussjukdomar

July 3, 2020

Cision Promoted: Emission teckningsoptioner ska driva två projekt genom fas II

June 30, 2020

Aktiespararna: Intensiv höst med sikte på utlicensiering i horisonten

June 2, 2020

BIOSTOCK: SynAct närmar sig studiestart efter myndighetsgodkännande

May 12, 2020

Redeye: Interview with CEO Jeppe Øvlesen and CSO Thomas Jonassen (video call)

May 6, 2020

BIOSTOCK: SynAct comments on positive Phase II data

April 2, 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19

April 2, 2020

BIOSTOCK: SynAct Pharma om Covid-19-satsningen (in Swedish)

April 1, 2020

Synact Pharma in spotlightanalysen (in Swedish)

April 1, 2020

Medwatch: Synact rekrutterer fortsat til forsøg trods pandemi (in Danish)

March 31, 2020

Life Science Sweden: Vill dämpa lunginflammationen vid covid-19 (in Swedish)

March 31, 2020

Medwatch: Synact Pharma vil teste hovedkandidat som tillægsbehandling til coronasyge patienter (in Danish)

March 31, 2020

Dagens Industri: Spotlight-bolag planerar preparattester på coronapatienter (in Swedish)

  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe